Tri Locum Partners’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Tri Locum Partners’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-51,750	Closed	-$6.14M	–	66
2022 Q1	$6.14M	Buy	51,750 +27,404	+113%	+$3.42M	2.4%	22
2021 Q4	$3.35M	Buy	+24,346	New	+$3.1M	1.32%	21
2021 Q1	–	Sell	-19,832	Closed	-$1.7M	–	84
2020 Q4	$1.7M	Buy	+19,832	New	+$1.68M	0.62%	30

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tri Locum Partners's BHVN Position: Q2 2022 in Review

Tri Locum Partners sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 51,750 shares — an estimated $6.14M sold.

Tri Locum Partners first reported a position in BHVN in Q4 2020 and held it in 3 quarters. The position peaked at $6.14M in Q1 2022. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

Tri Locum Partners reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
Tri Locum Partners sold 51,750 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $6.14M.
Tri Locum Partners first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2020 and held it in 3 quarters.
Tri Locum Partners's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $6.14M in Q1 2022.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Tri Locum Partners's 13F filing for Q2 2022, filed 15 Aug 2022.